FDA Regulatory, Healthcare Compliance, Market Access and Reimbursement, Privacy

FDA’s Warning Letters Send a Clear Signal: Unapproved Drugs Are in the Crosshairs

CDER’s Office of Unapproved Drugs and Labeling Compliance (“OFDL”) has taken the lead in addressing high-priority enforcement areas involving unapproved new drugs. Over the course of 2026, OFDL has issued warning letters concerning violations of the Federal Food, Drug, and Cosmetic Act’s (“FD&C Act”) prohibition on introducing unapproved new drugs into interstate commerce, focusing on issues including ketamine, peptides, and, most recently, drugs making claims related to sexually transmitted infections (“STIs”). See FD&C Act §§ 301(d), 505(a), 21 U.S.C. §§ 331(d), 355(a). FDA’s 2026 internet-pharmacy warning-letter listings, Peptide Partners warning letter, and October 1 Aidance Scientific warning letter illustrate those areas of activity. On October 1, FDA issued multiple warning letters addressing STI-related claims. Taken together, these actions signal that companies marketing products with such claims may face FDA scrutiny.

To understand FDA’s approach to these cases, it is first helpful to understand how the FD&C Act defines the term “drug.” Under FD&C Act § 201(g)(1), 21 U.S.C. § 321(g)(1), the term includes an article that:

  1. Is recognized in the United States Pharmacopeia, Homeopathic Pharmacopeia of the United States, or National Formulary, or a supplement to any of them;
  2. Is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans or other animals;
  3. Is not food and is intended to affect the structure or any function of the body of humans or other animals; or
  4. Is intended for use as a component of an article described in one of the categories above.

The statute also contains qualifications for certain compliant food and dietary-supplement claims. FD&C Act § 201(g)(1), 21 U.S.C. § 321(g)(1).

This definition is important because identifying a product as a drug is the beginning, not the end, of the marketing analysis. A drug may also be a “new drug” if it is not generally recognized by qualified experts as safe and effective for the conditions of use described in its labeling. FD&C Act § 201(p), 21 U.S.C. § 321(p). Generally, potential routes to market for a human drug include a full New Drug Application (“NDA”) under § 505(b)(1), an NDA relying in part on information the applicant does not own under § 505(b)(2), sometimes called a “paper NDA”, an Abbreviated New Drug Application (“ANDA”) under § 505(j), or, where its requirements are met, marketing without a product-specific approved application under the OTC monograph framework in § 505G. FD&C Act §§ 505(b), (j), 505G, 21 U.S.C. §§ 355(b), (j), 355h (§ 505G). The OTC framework turns on conformity with applicable conditions under which a nonprescription drug is generally recognized as safe and effective (“GRASE”); GRASE is not itself an additional type of application. See 21 U.S.C. § 355h; 21 C.F.R. § 330.1. Thus, determining whether a product is a “drug” is only the first step, the next question is whether the product has an appropriate legal basis for marketing in the United States.

With that framework in mind, the following analysis examines FDA’s October 1, 2026 warning letter to The Platinum Healthcare LLC, MARCS-CMS 735147 (“Platinum Healthcare”). The letter provides an example of how FDA is applying the FD&C Act to products making claims related to STIs.

In the warning letter, FDA stated that Platinum Healthcare’s “Sycosis” and “Syphillinum” products are unapproved new drugs. FDA identified them as drugs under FD&C Act § 201(g)(1), 21 U.S.C. § 321(g)(1), and as new drugs under § 201(p), 21 U.S.C. § 321(p), because they were not generally recognized as safe and effective for their intended uses. FDA further stated that no applications approved under § 505, 21 U.S.C. § 355, were in effect for them, and that their introduction or delivery for introduction into interstate commerce violated §§ 301(d) and 505(a), 21 U.S.C. §§ 331(d) and 355(a).

The basis for FDA’s determination becomes clear when looking at the claims Platinum Healthcare made for the products on its website. FDA identified, among others, the following claims:

  • For Sycosis: “Oral antigen for desensitizing and stimulating the body’s immune defense mechanism against problems caused by the Gonorrhea miasm.”
  • For Syphillinum: “Oral antigen for desensitizing and stimulating the body’s immune defense mechanism against problems caused by the Syphilis miasm.”

These claims are significant because intended use is central to whether an article meets the statutory definition of a drug. FD&C Act § 201(g)(1)(B)–(C), 21 U.S.C. § 321(g)(1)(B)–(C). FDA’s intended-use regulation explains that objective intent may be shown by, among other things, labeling claims, advertising, statements, product design or composition, and circumstances of distribution. 21 C.F.R. § 201.128. Here, FDA viewed the claims concerning the body’s immune defenses and conditions associated with gonorrhea and syphilis as evidence of drug intended uses. The products’ characterization as homeopathic did not, in FDA’s view, exempt them from the FD&C Act’s drug requirements.

Once FDA determined that the products were drugs, it considered whether they were new drugs and whether an approved application permitted their marketing. According to FDA, they were not GRASE for their intended uses, and no approved applications were in effect. FD&C Act §§ 201(p), 505(a), 21 U.S.C. §§ 321(p), 355(a). FDA stated: “No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).”

Thus, the Platinum Healthcare warning letter illustrates FDA’s enforcement theory. First, FDA examined the claims made for the products as evidence of intended use. 21 C.F.R. § 201.128. Second, FDA determined that the products met the statutory definition of drugs and were new drugs because they were not GRASE for those uses. FD&C Act § 201(g)(1), (p), 21 U.S.C. § 321(g)(1), (p). Finally, finding no approved applications in effect, FDA concluded that introducing or delivering the products for introduction into interstate commerce violated FD&C Act §§ 301(d) and 505(a), 21 U.S.C. §§ 331(d) and 355(a).

But the significance of these warning letters extends beyond the specific products identified in them. The recent actions also provide evidence of where FDA has directed enforcement attention. FDA cannot investigate every website or manufacturer at once. Its 2026 letters concerning internet pharmacies, peptide products, and STI-related claims are therefore useful indicators of recent enforcement activity, although individual warning letters do not themselves establish a comprehensive or permanent agency priority.

For companies subject to FDA regulation, understanding the statutory and regulatory framework is therefore only part of the equation. It is also important to monitor how FDA is applying that framework. The recent OFDL warning letters remind companies to evaluate both the legal basis for marketing a product, including its intended use, new-drug status, and any applicable approval or OTC route, and the claims and practices attracting current scrutiny. See FD&C Act §§ 201(g)(1), 201(p), 505(a), and 505G, 21 U.S.C. §§ 321(g)(1), (p), 355(a), and 355h; 21 C.F.R. § 201.128.